Technology

Learn more about Hexima’s technology.
 

HXP124

Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.

Latest news

AGM 2019 – Presentation and Results

Presentations and Results from the 2019 Hexima Limited Annual General Meeting held 19 November 2019. AGM 2019 Chairman’s Address AGM 2019 CEO Presentation AGM 2019 Meeting Results

AGM 2019 – Hexima Limited Notice of Annual General Meeting

Please be advised that the Hexima Limited 2019 Annual General Meeting (AGM) will be held at 3:30pm on Tuesday, 19 November 2019 at MinterEllison, Level 23, Rialto Towers, 525 Collins Street, Melbourne, Victoria. Registration will commence at 3:00pm. A letter from the...

Hexima announces appointment of Michael Aldridge

Hexima Limited is pleased to announce the appointment of Mr Michael Aldridge as Chief Business Officer and a member of the Board of Directors, effective 21 May 2019. Mr Aldridge will be based in San Francisco, focussing on business development and establishing...

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo